文献速递妇科

卵巢癌中NF1失活的替代免疫组化调查研究

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
PubMed 文献 · Gynecol Oncol · 2023-10-09

研究在2140例卵巢癌组织芯片上用NF1抗体(克隆NFC)免疫组化检测NF1失活,高级别浆液性癌中失活率为17.4%(250/1429),低级别浆液性癌为5.9%(4/64),子宫内膜样癌为7.3%(21/286);NF1失活与CCNE1扩增互斥,与RB1缺失共存,在BRCA1/2突变型与野生型中频率相似。

要点

  • 高级别浆液性卵巢癌中NF1失活率为17.4%(250/1429),其中11%为亚克隆性失活。
  • NF1失活与CCNE1高水平扩增互斥,与RB1缺失共存,在BRCA1/2突变型与野生型中频率相似。
  • 子宫内膜样癌NF1失活率为7.3%(21/286),与良好预后相关(p=0.048)。

核心结论

  • NF1失活在BRCA1/2野生型高级别浆液性癌的显著亚群及低级别浆液性癌亚群中发生,其功能效应需进一步表征,但提示针对NF1失活的潜在治疗机会。

研究设计与样本

  • 在自动化免疫组化平台上正交验证新近商业化的NF1抗体(克隆NFC),并对包含2140例卵巢癌病例的组织芯片进行免疫组化检测。

主要发现

  • 高级别浆液性癌中NF1表达缺失为250/1429(17.4%),包括11%亚克隆性缺失。
  • NF1失活的高级别浆液性癌患者生存介于预后良好的BRCA1/2突变型与预后不良的CCNE1高水平扩增型之间。
  • NF1失活与CCNE1高水平扩增互斥,与RB1缺失共存,在BRCA1/2突变型与野生型高级别浆液性癌中发生频率相似。
  • 子宫内膜样癌中NF1缺失为21/286(7.3%),与良好预后相关(p=0.048)。
  • 低级别浆液性癌中NF1缺失为4/64(5.9%),与其他驱动事件互斥。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration in tubo-ovarian high-grade serous carcinoma (HGSC) is the genomic inactivation of neurofibromin 1 (NF1). The primary objectives of our study were to survey the prevalence of NF1 inactivation in the principal ovarian carcinoma histotype as well as to evaluate its associations with clinico-pathological parameters and key biomarkers including BRCA1/2 status in HGSC. METHODS: A recently commercialized NF1 antibody (clone NFC) was orthogonally validated on an automated immunohistochemistry (IHC) platform and IHC was performed on tissue microarrays containing 2140 ovarian carcinoma cases. Expression was interpreted as loss/inactivated (complete or subclonal) versus normal/retained. RESULTS: Loss of NF1 expression was detected in 250/1429 (17.4%) HGSC including 11% with subclonal loss. Survival of NF1-inactivated HGSC patients was intermediate between favorable BRCA1/2 mutated HGSC and unfavorable CCNE1 high-level amplified HGSC. NF1 inactivation was mutually exclusive with CCNE1 high-level amplifications, co-occurred with RB1 loss and occurred at similar frequencies in BRCA1/2 mutated versus wild-type HGSC. NF1 loss was found in 21/286 (7.3%) endometrioid carcinomas with a favorable prognostic association (p = 0.048), and in 4/64 (5.9%) LGSC, mutually exclusive with other driver events. CONCLUSIONS: NF1 inactivation occurs in a significant subset of BRCA1/2 wild-type HGSC and a subset of LGSC. While the functional effects of NF1 inactivation need to be further characterized, this signifies a potential therapeutic opportunity to explore targeting NF1 inactivation in these tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Köbel M, Yang RZ, Kang EY, et al. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas. Gynecol Oncol. 2023. PMID: 37820398. doi:10.1016/j.ygyno.2023.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。